Japan’s NDA Examination Period Shortest Since 2000
This article was originally published in PharmAsia News
Executive Summary
The median examination period for new drug applications in Japan in 2011 was 10.1 months, 4.7 months shorter than the previous year, according to a report from the Japan Pharmaceutical Manufacturers Association’s Office of Pharmaceutical Industry Research.